Molecular aberrations in the MHC class I-restricted pathway for antigen presentation in methylcholanthrene sarcomas from nude mice: Discrepancies between MHC mRNA and surface protein

Clinical and Experimental Immunology

Volumn 109, Issue 2, 1997, Pages 323-331

  Engel, A M ^a   Svane, I M ^a   Madsen, M W ^b   Pedersen, M ^a   Werdelin, O ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b DANISH CANCER SOCIETY RESEARCH CENTER   (Denmark)

Author keywords

Antigen presentation; MCA; MHC class I; mRNA; Nude mice; Tumours

Indexed keywords

3 METHYLCHOLANTHRENE; BETA 2 MICROGLOBULIN; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MESSENGER RNA;

ANIMAL EXPERIMENT; ANTIGEN PRESENTATION; ARTICLE; CARCINOGENESIS; CONTROLLED STUDY; FEMALE; MAJOR HISTOCOMPATIBILITY COMPLEX; MOUSE; NONHUMAN; NUDE MOUSE; PRIORITY JOURNAL; SARCOMA;

EID: 0030751624     PISSN: 00099104     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2249.1997.4361335.x     Document Type: Article

References (62)

1. Old LJ, Boyse EW, Clarke DA, Carswell EA. Antigenic properties of chemically induced tumors. Annals NY Acad Sci 1962; 101:80-105.
2. Wortzel RD, Philipps C, Schreiber H. Multiple tumor-specific antigens expressed on a single tumour cell. Nature 1983; 304:165-7.
3. Sadegh-Nasseri S, Germain RN. A role for peptide in determining MHC class II structure. Nature 1991; 353:167.
4. Melief CJM. Tumor eradication by adoptive transfer of cytotoxic T lymphocytes. Adv Cancer Res 1992; 58:143-75.
5. Klein G, Sjögren HO, Klein E, Hellström KE. Demonstration of resistance against methylcholanthrene induced sarcomas in the primary autochthonous host. Cancer Res 1960; 20:1561-72.
6. Mukherji B, Chakraborty NG, Sivanandham M. T cell clones that react against autologous human tumors. Immunolog Rev 1990; 116:33.
7. Van Pel A, Warnier G, van den Eynde B, Lethe B, Lurquin C, Boon T. Turn- antigens, TSTA, and T cell immune surveillance. Annals NY Acad Sci 1991; 636:43-51.
8. Roth C, Rochlitz C, Kourilsky P. Immune response against tumors. Adv Immunol 1994; 57:281-351.
9. Doherty PC, Knowles BB, Wettstein PJ. Immunological surveillance of tumors in the context of major histocompatibility complex restriction of T cell function. Adv Can Res 1984; 42:1-65.
10. Klein G. Immunological surveillance against neoplasia. Harvey Lect 1975; 69:71-102.
11. McMichael A. Cytotoxic T lymphocytes and immune surveillance. Cancer Surv 1992; 13:5-22.
12. Svane IM, Engel A, Nielsen M, Ljunggren H, Rygaard J, Werdelin O. Chemically induced sarcomas from nude mice are more immunogenic than similar sarcomas from congenic normal mice. Eur J Immunol 1996; 26:1844-50.
13. Engel A, Svane IM, Mouritsen S, Rygaard J, Clausen J, Werdelin O. Methylcholanthrene-induced sarcomas in nude mice have short induction times and relatively low levels of surface MHC class I expression. APMIS 1996; 104:629-39.
14. Pardoll DM. A new look for the 1990s. Nature 1994; 369:357-8.
15. Höglund P, Ljunggren HG, Kärre K, Jay G. Role of major histocompatibility complex class I molecules in tumor rejection. New insights from studies with synthetic peptides and transgenic mice. Immunol Res 1990; 9:298-313.
16. van der Bruggen P, van den Eynde B. Molecular definition of tumor antigens recognized by T lymphocytes. Curr Opin Immunol 1992; 4:608-12.
17. Cerottini J-C, von Fliedner V, Boon T. Recognition of tumor-associated antigens by T lymphocytes: from basic concepts to new approaches. Annals Oncol 1992; 3:11-16.
18. Rock KL, Gramm C, Rothstein L et al. Inhibitors of the proteasome block the degradation of most cell proteins and the generation of peptides presented on MHC class I molecules. Cell 1994; 78:761-71.
19. Srivastava PK, Udono H, Blachere NE, Li Z. Heat shock proteins transfer peptides during antigen processing and CTL priming. Immunogenetics 1994; 39:93-98.
20. Berzofsky JA, Berkover IJ. Immunogenecity and antigen structure. In: Paul WE, ed. Fundamental immunology, 3rd edn. New York: Raven Press, 1993:235-82.
21. Germain RN. MHC-dependent antigen processing and peptide presentation: providing ligands for T lymphocyte activation. Cell 1994; 76:287-99.
22. de Fougerolles AR, Springer TA. Characterization of the function of intercellular adhesion molecule (ICAM-3) 3 and comparison with ICAM-1 and ICAM-2 in immune responses. J Exp Med 1994; 179:619-29.
23. Aki M, Shimbara N, Takashina M et al. Interferon gamma induces different subunit organizations and functional diversity of proteasomes. J Biochem 1994; 115:257-69.
24. Belich MP, Glynne RJ, Senger G, Sheer D, Trowsdale J. Proteasome components with reciprocal expression to that of the MHC encoded LMP proteins. Curr Biol 1994; 4:769.
25. Boes B, Hengel H, Ruppert T, Multhaup G, Koszinowski UH, Kloetzel P. Interferon gamma stimulation modulates the proteolytic activity and cleavage site preference of 20S mouse proteasomes. J Exp Med 1994; 179:901-9.
26. Tanaka K. Role of proteasomes modified by interferon gamma in antigen processing. J Leuk Biol 1994; 56:571-575.
27. Rubin DM, Finley D. The proteasome: a protein-degrading organelle. Curr Biol 1995; 5:854-8.
28. Fehling HJ, Swat W, Laplace C et al. MHC class I expression in mice lacking the proteasome subunit LMP7. Science 1994; 265:1234-7.
29. Günther E. Heat shock protein genes and the major histocompatibility complex. In: Kaufmann SHE, ed. Heat shock proteins and immune response. Berlin: Springer-Verlag, 1991:57-70.
30. Kaufmann SHE. Heat shock proteins and the immune response. Immunol Today 1990; 11:129-36.
31. Li Z, Srivastava PK. A critical contemplation on the role of heat shock proteins in transfer of antigenic peptides during antigen presentation. Behring Inst Mitt 1994; 94:37-47.
32. Udono H, Srivastava PK. Heat shock protein 70 associated peptides elicit specific cancer immunity. J Exp Med 1993; 178:1391-6.
33. Srivastava PK. Peptide binding heat shock proteins in the endoplasmic reticulum: role in immune response to cancer and in antigen presentation. Adv Cancer Res 1993; 62:153-77.
34. Dustin ML, Rothlein R, Bhan AK, Dinarello CA, Springer TA. Induction by IL-1 and interferon gamma: tissue distribution, biochemistry and function of a natural adherence molecule (ICAM-1). J Immunol 1986; 137:245-54.
35. Bartlett GL. Effect of host immunity on the antigenic strength of primary tumors. J Natl Cancer Inst 1972; 49:493-504.
36. Madsen MW, Lykkesfeldt AE, Laursen I, Nielsen KV, Briand P. Altered gene expression of c-myc, epidermal growth factor receptor, transforming growth factor alpha and c-erb-B2 in an immortalized human breast epithelial cell line, HMT-3522, is associated with decreased growth factor requirements. Cancer Res 1992; 52:1210-7.
37. Fort P, Marty L, Piechaczyk M et al. Various rat adult tissues express only one major mRNA species from the glyceraldehyde-3-phosphate-dehydrogenase multigenic family. Nucleic Acids Res 1985; 13:1431.
38. Keeney JB, Hedayat M, Myers NM, Connolly JM, Hansen TH. Locus-specific regulation of Kd, Dd and Ld class I genes in the Balb/c S49 lymphoma sublines. J Immunol 1989; 143:2364-73.
39. Lalanne JL, Delarbre C, Gachelin G, Kourilsky P. A cDNA clone containing the entire coding sequence of a mouse H-2 histocompatibility antigen. Nucleic Acids Res 1983; 11:1567-77.
40. Daniel F, Morello D, Le Bail O, Chambon P, Cayre Y, Kourilsky P. Structure and expression of the mouse beta-2-microglobulin gene isolated from somatic and non-expressing teratocarcinoma cells. EMBO J 1983; 2:1061-5.
41. Hendil KB, Welinder KG, Pedersen D, Uerkvitz W, Kristensen P. Subunit stoichiometry of human proteasomes. Enzyme Protein 1993; 47:232-40.
42. Ljunggren H, Stam NJ, Öhlen C et al. Empty MHC class I molecules come out in the cold. Nature 1990; 346:476-80.
43. Petersson MGE, Kärre K, Cochet M, Kourilsky P, Kiessling R. An active T cell independent mechanism enhances MHC class I transcription and expression on a mouse T cell lymphoma in vivo. Cell Immunol 1987; 198:460-72.
44. Aboud M, Amitai H, Huleihel M, Har-Vardi I, Gopas J, Segal S. Differential transcriptional control of the H-2K and H-2D loci of the major histocompatibility complex in fibrosarcoma cells. Immunol Invest 1991; 20:475-85.
45. Groettrup M, Kraft R, Kostka S, Standera S, Stohwasser R, Kloetzel P. A third interferon-gamma induced subunit exchange in the 20S proteasome. Eur J Immunol 1996; 26:863-9.
46. Histamatsu H, Shimbara N, Saito Y et al. Newly identified pair of proteasomal subunits regulated reciprocally by interferon gamma. J Exp Med 1996; 183:1807-16.
47. Blanchet O, Bourge JF, Zinszner H, Tatari Z, Degos L, Paul P. DNA binding of regulatory factors interacting with MHC class I gene enhancer correlates with MHC class I transcriptional level in class I defective cell lines. Int J Cancer 1991; 6:138-45.
48. Doyle A, Martin WJ, Funa K et al. Markedly decreased expression of class I histocompatibility antigens, protein, and mRNA in human small cell lung cancer. J Exp Med 1985; 161:1135-51.
49. Ruiz-Cabello F, Perez-Ayala M, Gomez O et al. Molecular analysis of MHC class I alterations in human tumor cell lines. Int J Cancer 1991; 6:123-30.
50. Schrier PI, Versteeg R, Peltenburg LTC, Plomp AC, van't Veer LJ, Krüse-Wolters KM. Sensitivity of melanoma cell lines to natural killer cells: a role for oncogene modulated HLA class I expression. Semin Cancer Biol 1991; 2:73-83.
51. Schrier PI, Peltenburg LTC. Relationship between myc oncogene activation and MHC class I expression. Adv Cancer Res 1993; 60:181-246.
52. Rosa F, Berissi H, Weissenbach J, Maroteaux L, Fellous M, Revel M. The beta 2 microglobulin mRNA in human Daudi cells has a mutated initiation codon but is still inducible by interferon. EMBO J 1983; 2:239-43.
53. D'Urso C, Wang Z, Cao Y, Tatake R, Zeff RA, Ferrone S. Lack of HLA class I antigen expression by cultured melanoma cells F-0-1 due to a defect in beta 2-microglobulin expression. J Clin Invest 1991; 87:284-92.
54. Wang Z, Cao Y, Albino AP, Zeff RA, Houghton AN, Ferrone S. Lack of HLA class I antigen expression by melanoma cells SK-MEL-33 caused by a reading frameshift in beta 2-microglobulin messenger RNA. J Clin Invest 1993; 91:684-92.
55. Bicknell DC, Rowan A, Bodmer WF. Beta-2-microglobulin gene mutations: a study of established colorectal cell lines and fresh tumors. PNAS 1994; 91:4751-5.
56. Gaforio JJ, Perez M, Algarra I, Mialdea MJ, Ljunggren H, Garrido F. Differential mRNA levels of c-myc, c-fos and MHC class I in several clones of a murine fibrosarcoma. Int J Cancer 1991; 49:906-10.
57. Restifo NP, Esquivel F, Asher AL et al. Defective presentation of endogenous antigens by a murine sarcoma. Implications for the failure of an anti-tumor immune response. J Immunol 1991; 147:1453-9.
58. Srivastava PK, Maki RG. Stress induced proteins in immune response to cancer. In: Kaufmann SHE, ed. Heat shock proteins and immune response. Berlin: Springer-Verlag, 1991:109-24.
59. Ferrarini M, Heltai S, Zocchi MR, Rugarli C. Unusual expression and localization of heat shock proteins in human tumor cells. Int J Cancer 1992; 51:613-9.
60. Jäättelä M, Wissing D. Emerging role of heat shock proteins in biology and medicine. Ann Med 1992; 24:249-58.
61. Keating PJ, Cromme FV, Duggan-Keen M et al. Frequency of down-regulation of individual HLA-A and -B alleles in cervical carcinomas in relation to TAP-1 expression. Br J Cancer 1995; 72:405-11.
62. Cromme FV, Airey H, Heemels M-T et al. Loss of transporter protein, encoded by the TAP-1 gene, is highly correlated with loss of HLA expression in cervical carcinoma. J Exp Med 1994; 179:335-40.